<DOC>
	<DOCNO>NCT02618122</DOCNO>
	<brief_summary>This non-interventional study aim primarily assess clinical effectiveness impact therapy cancer-related symptom patient ' HRQoL . In addition , represent attempt towards gain experience routine use trabectedin daily clinical practice representative sample Greek subject aSTS .</brief_summary>
	<brief_title>A Multicenter , Prospective , oBservational Study assEss Clinical activitY Impact symptOm Burden patieNts ' HRQoL Treatment With trabecteDin aSTS Real World Setting Greece</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Patients eligible inclusion study meet follow criterion : Adult outpatient ( 18 year old ) either gender ; Patients histologically confirm diagnosis advance ( locally advance metastatic ) soft tissue sarcoma fail treatment anthracyclines ifosfamide unsuited receive drug ; Patients decision prescribe therapy trabectedin ( YondelisÂ® ) accord locally approve product 's summary product characteristic ( SmPC ) already take prior enrolment study clearly separate physician 's decision include patient current study ; Patients must able willing provide write informed consent comply requirement study protocol ; Patients must sign informed consent document ; Patients must able read , understand complete study specific questionnaire . A patient meet follow criterion exclude participation study : Patients receive one cycle trabectedin time enrolment study ; Patients meet contraindication administration study drug accord approve SmPC ; Patients currently receive treatment investigational drug/device/intervention receive investigational product within 1 month 5 halflives investigational agent ( whichever longer ) commencement therapy trabectedin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>